Streetbeat News

Earnings Revenues

CIVI

Rosen Law Firm is investigating potential securities claims against Civitas Resources (CIVI) following an earnings miss and unexpected executive terminations. On February 24, 2025, the company reported quarterly revenue below consensus estimates and announced the immediate termination of its chief operating and transformation officers. As a result, CIVI's stock price dropped 18% on February 25, 2025.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

MU

Micron Technology (MU) is experiencing a challenging period marked by declining sequential profitability, substantial pricing pressures in the semiconductor market, and negative technical indicators. The stock has dropped 8%, signaling potential investor concerns about the company's near-term financial performance and market positioning.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

OCX

Oncocyte Corporation reported Q4 2024 financial results, highlighting $1.5 million in pharma services revenue and $1.9 million for the full year. Key achievements include launching the GraftAssure RUO assay, securing a strategic partnership with Bio-Rad Laboratories, and advancing transplant science with expanded Medicare claims. The company is positioned to develop a regulated organ transplant rejection monitoring test kit in 2025.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

NXGL

NEXGEL reported strong financial performance for the fourth quarter of 2024, with revenue reaching $3.04 million, a significant 181% increase compared to $1.08 million in the same quarter of the previous year. This substantial growth indicates robust business expansion and potential market momentum.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

AURA

Aura Biosciences announced its fourth quarter and full year 2024 financial results, highlighting positive Phase 1 trial data for its non-muscle invasive bladder cancer (NMIBC) treatment. The data was presented at the 40th Annual European Association of Urology Congress, suggesting potential for front-line treatment applications.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

PREKF

PrairieSky Royalty Ltd. will release its Q1 2025 financial results on Monday, April 14, 2025 after market close, with a subsequent conference call for investors on Tuesday, April 15, 2025 at 6:30 am MT. The company, a royalty-focused enterprise generating revenues from petroleum and natural gas production, will provide operating and financial information through a news release and make financial statements available on their website and SEDAR+.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

AFIB

Acutus Medical, a medical device company, has released its full year 2024 financial results. The announcement provides insights into the company's annual financial performance, offering shareholders and investors a comprehensive view of its fiscal health for the past year.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

SKYX

SKYX Platforms Corp. reported strong financial results for 2024, with revenues increasing from $58.8 million in 2023 to $86.3 million in 2024. The company achieved four consecutive quarters of revenue growth, with Q4 2024 generating a record $23.7 million. SKYX expects to have its advanced and smart home products in 20,000 units/homes by Q1 2025 and anticipates becoming cash flow positive in the second half of 2025.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

AWF

AllianceBernstein Global High Income Fund, Inc. (AWF) released its monthly portfolio update for February 28, 2025, detailing its top 10 fixed-income holdings. The portfolio includes U.S. Treasury Notes, corporate bonds from CCO Holdings, NFE Financing LLC, EchoStar Corp., and international bonds from the Dominican Republic, among others.

Portfolio Pulse from

March 24, 2025 | 8:15 pm

XAIR

NeuroNOS, a subsidiary of Beyond Air, secured $2 million in initial equity financing to advance a novel small-molecule drug for Autism Spectrum Disorder (ASD). The therapy aims to regulate nitric oxide levels in the brain, with potential to improve behavioral and cognitive functions in children with autism. First-in-human studies are anticipated to begin in 2026, focusing on subcutaneous and potential oral formulations.

Portfolio Pulse from

March 24, 2025 | 8:15 pm